(UroToday.com) Clinical trials of immune checkpoint blockade (ICB) historically exclude patients with pre-existing autoimmune diseases because of concerns around decreased efficacy due to immunosuppression as well as toxicity. Real-world evidence suggests that immune-related adverse events associated with immune checkpoint blockade are manageable in patients with pre-existing autoimmune disease. In this presentation, Dr. Hoffman-Censits and colleagues present data from the US administrative claims database concerning pre-existing autoimmune disease and immune checkpoint blockade in patients with metastatic urothelial cancer (mUC).